Pancreatic Cancer Research

ResearcherUniversity of PittsburghNo recent work listed

Arthur James Moser

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9825-9621; OpenAlex author ID A5007794069. Sources: ClinicalTrials.gov.

Their work

Papers
20 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2012: 1 paper · 2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: none · 2018: 5 papers, 1 trial · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper

Papers 20

  1. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Co-author DOI 10.14309/ctg.0000000000000468↗
  2. Artificial intelligence to assess body composition on routine abdominal CT scans and predict mortality in pancreatic cancer- A recipe for your local applicatio… Co-author DOI 10.1016/j.ejrad.2021.109834↗
  3. Elevated levels of mitochondrial CoQ10 induce ROS-mediated apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41598-021-84852-z↗
  4. Biliary palliation for unresectable pancreatic adenocarcinoma: surgical bypass or self-expanding metal stent? Last author DOI 10.1016/j.hpb.2019.08.014↗
  5. Incidental pulmonary embolism in pancreatic ductal adenocarcinoma: Impact of tumor and AJCC stages at initial staging CT. Co-author DOI 10.1016/j.pan.2019.09.002↗
  6. DWI of Pancreatic Ductal Adenocarcinoma: A Pilot Study to Estimate the Correlation With Metastatic Disease Potential and Overall Survival. Co-author DOI 10.2214/ajr.18.20017↗
  7. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.31628↗
  8. Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls. Co-author DOI 10.1007/s00261-018-1459-6↗
  9. What Patients Look for When Browsing Online for Pancreatic Cancer: The Bait Behind the Byte. Co-author DOI 10.1007/s00268-018-4719-2↗
  10. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. Co-author DOI 10.1007/s11605-017-3541-8↗
  11. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.12.004↗
  12. Assessing the Accuracy and Readability of Online Health Information for Patients With Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2016.0730↗
  13. A Tale of Two Cities: Reconsidering Adjuvant Radiation in Pancreatic Cancer Care. Co-author DOI 10.1007/s11605-015-2951-8↗
  14. Early surgical bypass versus endoscopic stent placement in pancreatic cancer. Co-author DOI 10.1016/j.hpb.2016.05.008↗
  15. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4566-4↗
  16. Rankings versus reality in pancreatic cancer surgery: a real-world comparison. Co-author DOI 10.1111/hpb.12171↗
  17. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Co-author DOI 10.1186/1748-717x-8-240↗
  18. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Co-author DOI 10.1186/1748-717x-8-254↗
  19. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pan… Last author DOI 10.1245/s10434-013-3161-9↗
  20. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic adenocarcinoma following neoadjuvant therapy. Co-author DOI 10.1007/s11605-012-1839-0↗

Trials 1

  1. Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Principal investigator NCT03469258↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tara Sotsky Kent · 8 shared papers, 2014–2020 · strength 0.58
  2. Mark P. Callery · 6 shared papers, 2014–2020 · strength 0.44
  3. Alessandra Storino · 4 shared papers, 2016–2020 · strength 0.32
  4. Koenraad J. Mortelé · 3 shared papers, 2018–2019 · strength 0.32
  5. Jennifer F. Tseng · 5 shared papers, 2014–2018 · strength 0.32
  6. Susanna W.L. de Geus · 4 shared papers, 2016–2018 · strength 0.28
  7. Herbert J. Zeh · 6 shared papers, 2012–2018 · strength 0.23
  8. Randall E. Brand · 3 shared papers, 2013–2022 · strength 0.22
  9. Alejandro Garces-Descovich · 2 shared papers, 2018–2019 · strength 0.22
  10. Alexander L. Vahrmeijer · 3 shared papers, 2016–2018 · strength 0.22
  11. Khoschy Schawkat · 2 shared papers, 2019–2021 · strength 0.22
  12. Mariam F. Eskander · 3 shared papers, 2016–2018 · strength 0.19
  13. Nathan Bahary · 4 shared papers, 2013–2018 · strength 0.17
  14. Gyulnara G. Kasumova · 2 shared papers, 2018 · strength 0.16
  15. Amer H. Zureikat · 4 shared papers, 2012–2018 · strength 0.16
  16. Andrea J. Bullock · 2 shared papers, 2016–2018 · strength 0.15
  17. Joseph Douglas Mancias · 2 shared papers, 2016–2018 · strength 0.15
  18. Linda Dexlin Mellby · 1 shared paper, 2022 · strength 0.13
  19. Svein Olav Bratlie · 1 shared paper, 2022 · strength 0.13
  20. Thomas Charles King · 1 shared paper, 2022 · strength 0.13
  21. Bryson W. Katona · 1 shared paper, 2022 · strength 0.13
  22. Alfredo Carrato · 1 shared paper, 2022 · strength 0.13
  23. Aimee Lee Lucas · 1 shared paper, 2022 · strength 0.13
  24. Daniel C. Chung · 1 shared paper, 2022 · strength 0.13
  25. Julie Earl · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.